- Home
- CLLS vs SABA Comparison
CLLS vs SABA Comparison
Compare CLLS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.22
Company Overview
Basic Information| Metric | CLLS | SABA |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 225.6M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CLLS | SABA |
|---|---|---|
| Price | $3.22 | $8.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | 32.4K | ★ 46.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $7.96 |
| 52 Week High | $5.48 | $9.46 |
Technical Indicators
Market Signals| Indicator | CLLS | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 41.21 |
| Support Level | $3.05 | $8.23 |
| Resistance Level | $3.83 | $8.68 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 24.19 | 13.83 |
Price Performance
Historical Comparison CLLS
SABA
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.